| Literature DB >> 28050258 |
Katja Boehm1, Bettina Berger1, Thomas Ostermann2, Peter Heusser1.
Abstract
OBJECTIVE: It was the aim of this bibliometric analysis to identify all publications dealing with so-called 'context effects/placebo effects' to bring some organisation into the publication landscape of the past 35 years.Entities:
Keywords: Context effects; bibliometric analysis; meaning response; non-specific effects; placebo effects; review
Year: 2016 PMID: 28050258 PMCID: PMC4959145 DOI: 10.1177/2054270416643890
Source DB: PubMed Journal: JRSM Open ISSN: 2054-2704
Extracted data classified according to place of origin and year of publication.
| Origin | Year | |||
|---|---|---|---|---|
| Americaa (n = 147) | Europe and Rest (n = 154) | ≤2000 (n = 122) | >2000 (n = 179) | |
| Condition[ | ||||
| Healthy | 34 (23.1%) | 43 (27.9%) | 19 (15.6%) | 58 (32.4%) |
| Depression | 14 (9.5%) | 18 (11.7%) | 11 (9.0%) | 21 (11.7%) |
| Various | 5 (3.4%) | 10 (6.5%) | 5 (4.1%) | 10 (5.6%) |
| Hypertension | 8 (5.4%) | 4 (2.6%) | 10 (8.2%) | 2 (1.1%) |
| Migraine | 6 (4.1%) | 5 (3.2%) | 3 (2.5%) | 8 (4.5%) |
| Irritable Bowel Syndrome | 5 (3.4%) | 3 (1.9%) | 0 | 8 (4.5%) |
| Panic disorder | 3 (2.0%) | 4 (2.6%) | 5 (4.1%) | 2 (1.1%) |
| Main focus[ | ||||
| Placebo effects | 36 (24.5%) | 30 (19.5%) | 46 (37.7%) | 20 (11.2%) |
| Placebo response | 30 (20.4%) | 22 (14.3%) | 24 (19.7%) | 28 (15.6%) |
| Placebo responders | 4 (2.7%) | 10 (6.5%) | 4 (3.3%) | 10 (5.6%) |
| Placebo effects, expectation | 8 (5.4%) | 4 (2.6%) | 0 | 12 (6.7%) |
| Placebo analgesia | 4 (2.7%) | 4 (2.6%) | 1 (0.8%) | 7 (3.9%) |
| Placebo effects, expectancy | 4 (2.7%) | 4 (2.6%) | 7 (5.7%) | 1 (0.6%) |
| Placebo effects, placebo response | 4 (2.7%) | 4 (2.6%) | 6 (4.9%) | 2 (1.1%) |
| Journal type[ | ||||
| Specific condition | 28 (19.0%) | 26 (16.9%) | 34 (27.9%) | 20 (11.2%) |
| Pain | 23 (15.7%) | 17 (11.0%) | 14 (11.5%) | 26 (14.5%) |
| Psychiatry | 17 (11.6%) | 16 (11.7%) | 18 (14.8%) | 17 (9.5%) |
| Psychopharmacology | 6 (4.1%) | 14 (9.1%) | 10 (8.2%) | 10 (5.6%) |
| Neurology | 13 (8.9%) | 11 (7.1%) | 5 (4.1%) | 19 (10.7%) |
| General Medicine | 9 (6.1%) | 10 (6.5%) | 10 (8.2%) | 9 (5.0%) |
| Research | 8 (5.4%) | 10 (6.5%) | 3 (2.5%) | 15 (8.4%) |
| Publication type[ | χ2 = 0.000 (df = 7) | |||
| Meta-analysis | 17 (11.6%) | 29 (18.8%) | 8 (6.6%) | 38 (21.2%) |
| SR | 12 (8.2%) | 5 (3.2%) | 7 (5.7%) | 10 (5.6%) |
| RCT | 49 (33.3%) | 58 (37.7%) | 37 (30.3%) | 71 (39.7%) |
| CCT | 37 (25.2%) | 32 (20.8%) | 43 (35.2%) | 25 (14.0%) |
| UCT | 21 (14.3%) | 21 (13.6%) | 20 (16.4%) | 22 (12.3%) |
SR: systematic review; RCT: randomized controlled trial; CCT: clinical controlled trial; UCT: uncontrolled clinical trial.
Includes the whole continent.
Top most frequent items represented, therefore % does not add up to 100.